Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer

Published:2014-01-31 Issue:5 Volume:95 Page:558-564
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Wang J,Song P,Schrieber S,Liu Q,Xu Q,Blumenthal G,Amiri Kordestani L,Cortazar P,Ibrahim A,Justice R,Wang Y,Tang S,Booth B,Mehrotra N,Rahman A

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference31 articles.

1. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

2. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

3. Gemcitabine and ISIS-2503 for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Trial

4. Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model‐informed dose selection for an investigational human epidermal growth factor receptor 2 antibody–drug conjugate FS‐1502 in patients with human epidermal growth factor receptor 2‐expressing advanced malignant solid tumours;British Journal of Clinical Pharmacology;2024-01-25

2. Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road ahead;Critical Reviews in Oncology/Hematology;2023-02

3. Microporous affinity membranes and their incorporation into microfluidic devices for monitoring of therapeutic antibodies;Talanta;2023-01

4. Discovery and development of ADCs: obstacles and opportunities;Overcoming Obstacles in Drug Discovery and Development;2023

5. Applying interpretable machine learning workflow to evaluate exposure–response relationships for large‐molecule oncology drugs;CPT: Pharmacometrics & Systems Pharmacology;2022-10-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3